Johnson & Johnson Q2 2026 Analysis: Johnson & Johnson (NYSE: JNJ) reported second-quarter 2026 financial results on July 15, 2026, posting worldwide sales of $25.3 billion, a 6.6% reported increase over the $23.7 billion recorded in the same period last year. Operational sales growth came in at 5.6%, while adjusted operational sales growth reached 5.7%, according to the company’s official earnings release from New Brunswick, N.J.
Second-quarter earnings per share (EPS) landed at $2.27 on a reported basis, down slightly from $2.29 a year earlier, while adjusted EPS climbed to $2.90, up 4.7% year-over-year. Net earnings were roughly flat at $5.53 billion, but adjusted net earnings rose 5.7% to $7.08 billion. Free cash flow was estimated at approximately $8.7 billion for the year to date, a notable jump from $6.2 billion in the prior-year period.
Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges.
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson
Q2 2026 Financial Highlights
| Metric | Q2 2026 | Q2 2025 | % Change |
| Reported Sales ($M) | $25,310 | $23,743 | 6.6% |
| Net Earnings ($M) | $5,534 | $5,537 | (0.1%) |
| EPS (diluted) | $2.27 | $2.29 | (0.9%) |
| Operational Sales Growth | – | – | 5.6% |
| Adjusted Operational Sales Growth | – | – | 5.7% |
| Adjusted Net Earnings ($M) | $7,081 | $6,699 | 5.7% |
| Adjusted EPS (diluted) | $2.90 | $2.77 | 4.7% |
| Free Cash Flow YTD ($M, estimated) | $8,700 | $6,214 | – |
Regionally, U.S. sales reached $14.5 billion, up 7.3% reported, while international sales totaled $10.8 billion, up 5.7% reported (3.4% operational). The U.S. continues to outpace international markets on an operational basis, a pattern consistent with prior quarters.
| Region ($ in Millions) | Q2 2026 | Q2 2025 | Reported % Change | Operational % Change |
| U.S. | $14,533 | $13,544 | 7.3% | 7.3% |
| International | $10,777 | $10,199 | 5.7% | 3.4% |
| Worldwide | $25,310 | $23,743 | 6.6% | 5.6% |
Segment Performance Anchors This Johnson & Johnson Q2 2026 Analysis
| Segment ($ in Millions) | Q2 2026 | Q2 2025 | Reported % Change | Operational % Change |
| Innovative Medicine | $16,384 | $15,202 | 7.8% | 6.8% |
| MedTech | $8,926 | $8,541 | 4.5% | 3.6% |
| Worldwide | $25,310 | $23,743 | 6.6% | 5.6% |
Innovative Medicine: Oncology and Immunology Lead Growth
Innovative Medicine worldwide operational sales grew 6.8% in the quarter, with divestitures shaving roughly 10 basis points off growth. The gains were driven primarily by DARZALEX, CARVYKTI, TECVAYLI, and RYBREVANT/LAZCLUZE in oncology, along with TREMFYA and other immunology products, plus SPRAVATO and CAPLYTA in neuroscience. Growth was partially offset by continued erosion from STELARA, which lost patent exclusivity and dragged growth down by an estimated 760 basis points, along with declines in REMICADE, IMBRUVICA, and ZYTIGA.
MedTech: Surgery and Cardiovascular Drive the Segment
MedTech worldwide operational sales rose 3.6%, with net acquisitions and divestitures reducing growth by roughly 10 basis points. Wound closure and biosurgery products led growth within Surgery, while electrophysiology products and Shockwave technology powered Cardiovascular. Contact lenses in Vision and trauma products in Orthopaedics also contributed positively to the quarter.
Full-Year 2026 Guidance Raised
A central takeaway from this Johnson & Johnson Q2 2026 Analysis is the company’s decision to raise full-year guidance for the second consecutive update. Johnson & Johnson now projects estimated reported sales of $101.1 billion at the midpoint, representing 7.3% growth, up from the $100.8 billion midpoint projected in April 2026.
| Guidance Metric | July 2026 (Current) | April 2026 (Prior) |
| Adjusted Operational Sales Growth (Midpoint) | 6.5% | 6.1% |
| Estimated Reported Sales (Midpoint) | $101.1B / 7.3% growth | $100.8B / 7.0% growth |
| Adjusted Operational EPS (Midpoint) | $11.58 / 7.3% growth | $11.40 / 5.7% growth |
| Adjusted EPS (Midpoint) | $11.68 / 8.2% growth | $11.55 / 7.1% growth |
Adjusted EPS guidance increased by $0.13 to a midpoint of $11.68, while adjusted operational EPS guidance rose $0.18 to a midpoint of $11.58. Johnson & Johnson does not provide forward-looking GAAP guidance, citing the unpredictability of legal proceedings, unusual gains and losses, and acquisition-related accounting adjustments.
Pipeline and Regulatory Milestones Behind the Numbers
Beyond the topline figures, this Johnson & Johnson Q2 2026 Analysis would be incomplete without the regulatory and pipeline catalysts the company flagged for the quarter. On the approvals side, TREMFYA received a label expansion making it the only IL-23 inhibitor shown to help stop further structural joint damage in active psoriatic arthritis. CAPLYTA (lumateperone) gained FDA approval for reducing relapse risk in schizophrenia, and the Dual Energy THERMOCOOL SMARTTOUCH SF ablation platform received FDA clearance for cardiac procedures.
On the data-readout side, RYBREVANT FASPRO showed strong, durable responses in advanced head and neck cancer, an area with limited treatment options. TALVEY plus DARZALEX FASPRO demonstrated the strength of a bispecific antibody combination in earlier-line relapsed or refractory multiple myeloma. The company’s OTTAVA surgical robotic system also advanced with new data in upper abdominal procedures.
Corporate activity during the quarter included Johnson & Johnson’s announced acquisition of Firefly Bio to expand its oncology pipeline with a novel degrader-antibody conjugate platform, and a commitment to invest more than $1 billion to strengthen U.S. vision manufacturing in Jacksonville, Florida.
